Torrent Pharmaceuticals Limited

BSE:500420 株式レポート

時価総額：₹1.5t

Torrent Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Torrent Pharmaceuticalsの CEO はAman Mehtaで、 Aug2025年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は₹ 188.18Mで、 73.4%給与と26.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0%を直接所有しており、その価値は₹ 929.02K 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と5.6年です。

主要情報

Aman Mehta

最高経営責任者

₹188.2m

報酬総額

CEO給与比率73.43%
CEO在任期間less than a year
CEOの所有権0.00006%
経営陣の平均在職期間3.8yrs
取締役会の平均在任期間5.6yrs

経営陣の近況

Recent updates

ナラティブの更新 • Jun 04

500420: Diabetes And Obesity Portfolio Expansion Will Drive A More Upbeat Outlook

Analysts have raised their indicative fair value estimate for Torrent Pharmaceuticals from about ₹4,565 to roughly ₹4,879, reflecting expectations of steadier revenue growth, a higher profit margin, and a slightly richer future P/E assumption. What's in the News A board meeting is scheduled for 22 May 2026 to consider the audited financial results for the year ended 31 March 2026, a final dividend recommendation for 2025-26, potential fund raising via equity or convertible instruments, and other business matters.
ナラティブの更新 • May 12

500420: New Metabolic Launches And Dividend Payouts Will Shape Balanced Outlook

Analysts have nudged their fair value estimate for Torrent Pharmaceuticals from ₹4,540.32 to ₹4,564.93, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 22, 2026 to consider audited financial results for the year ended March 31, 2026 and a potential final dividend for 2025-26, along with enabling resolutions for possible equity fund raising, including convertible bonds or debentures and other modes (company filing).
ナラティブの更新 • Apr 21

500420: New Metabolic Franchise And Dividend Support Will Shape Balanced Future Outlook

Analysts have made a modest upward revision to Torrent Pharmaceuticals' price target to ₹4,540, from about ₹4,527. This reflects updated assumptions on slightly lower projected revenue growth, alongside marginally higher profit margin and future P/E expectations.
ナラティブの更新 • Apr 05

500420: New Metabolic Franchise And Dividend Plan Will Drive Future Upside

Analysts have lifted their price target on Torrent Pharmaceuticals slightly from about ₹4,499 to around ₹4,527, reflecting updated assumptions around revenue growth, profit margins and future P/E levels. What's in the News Torrent Pharmaceuticals launched its Semaglutide brands Sembolic and Semalix in India, offering both oral and injectable formulations that target metabolic disorders such as type 2 diabetes and obesity (Product announcement).
ナラティブの更新 • Mar 22

500420: Patent Dispute And Planned Dividends Will Shape Future Risk Balance

The analyst price target for Torrent Pharmaceuticals has shifted slightly higher to ₹4,498.68 from ₹4,487.96, with analysts pointing to stable assumptions around discount rate, revenue growth, profit margins, and a marginally higher future P/E multiple as the key drivers behind this refinement. What's in the News Xeris Biopharma Holdings and its subsidiaries filed a Hatch-Waxman patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics related to generic versions of Recorlev (levoketoconazole).
ナラティブの更新 • Mar 07

500420: Lawsuit And Dividend Decisions Will Shape Future Risk Balance

The updated analyst price target for Torrent Pharmaceuticals moves from roughly ₹4,418 to about ₹4,488, with analysts citing revised expectations for revenue growth and profit margins, as well as a modest adjustment in the assumed future P/E. What's in the News Xeris Biopharma Holdings filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics related to proposed generic versions of Recorlev (levoketoconazole) under the Hatch Waxman Act, seeking to block generic sales until the underlying patents, currently listed to March 2040, expire (Key Developments).
ナラティブの更新 • Feb 21

500420: Board Actions And Interim Dividend Will Shape Future Risk Balance

Analysts have revised their price target on Torrent Pharmaceuticals from ₹4,080 to ₹4,418, citing updated assumptions around revenue growth, profit margins and forward P/E as key drivers of this change. What's in the News Torrent Pharmaceuticals declared an interim dividend of ₹29 per equity share of ₹5, described as 580% of the face value, with payment or dispatch expected on or around 6 March 2026 (company announcement).
ナラティブの更新 • Feb 06

500420: Measured Growth And Board Actions Will Shape Future Risk Balance

Analysts have slightly trimmed their price target for Torrent Pharmaceuticals to reflect a lower assumed discount rate and a marginally reduced future P/E, while keeping fair value broadly unchanged and citing more measured expectations around growth and profitability. What's in the News A board meeting is scheduled for Jan 05, 2026, for the company to meet and review board matters on that date (company board communication).
ナラティブの更新 • Jan 23

500420: Patent Settlement And Margin Tweaks Will Shape Future Risk Balance

Analysts have inched up their fair value estimate for Torrent Pharmaceuticals from ₹4,048.88 to ₹4,080.22, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Torrent Pharmaceuticals has a board meeting scheduled on January 5, 2026.
ナラティブの更新 • Jan 09

500420: Patent Settlement And Margin Assumptions Will Shape Future Risk Balance

Analysts have nudged up their fair value estimate for Torrent Pharmaceuticals from ₹4,024.27 to ₹4,048.88, citing slightly stronger assumed profit margins and a marginally higher future P/E multiple in their updated models. What's in the News Torrent Pharmaceuticals has a Board Meeting scheduled on January 5, 2026, with details yet to be clarified for investors.
ナラティブの更新 • Dec 24

500420: Patent Settlement And Stable Outlook Will Shape Future Risk Profile

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target on Torrent Pharmaceuticals at ₹4,024. This reflects unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the current fair value assessment.
ナラティブの更新 • Dec 10

500420: Patent Settlement Will Shape U S Prospects While Outlook Remains Balanced

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target for Torrent Pharmaceuticals at ₹4,024, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins, and future valuation multiples, despite recent model refinements. What's in the News Eisai and Torrent Pharmaceuticals reached a patent infringement settlement over Lenvima in the U.S., allowing Torrent to launch its generic lenvatinib from July 1, 2030, subject to certain contingencies (Key Developments).
ナラティブの更新 • Nov 26

500420: Patent Litigation Outcome Will Influence U S Market Path After 2030

Analysts have raised their fair value estimate for Torrent Pharmaceuticals from ₹4,010.04 to ₹4,024.27. They cited modest improvements in projected revenue growth, even though there is a slight moderation in profit margin expectations.
ナラティブの更新 • Nov 10

500420: New Settlement Agreement Will Shape U S Market Opportunity After 2030

Analysts have raised their price target for Torrent Pharmaceuticals from ₹3,929 to ₹4,010, citing slightly improved revenue growth forecasts and higher projected profit margins. What's in the News Torrent Pharmaceuticals has entered into a settlement agreement with Eisai Co., Ltd.
ナラティブの更新 • Sep 05

Robust Indian And Brazilian Markets Will Unlock Potential

With both consensus revenue growth and net profit margin forecasts holding steady, analysts kept their price target for Torrent Pharmaceuticals unchanged at ₹3929. What's in the News Shareholders approved the appointment of Aman Mehta as Managing Director for five years, following his successful tenure as Whole-time Director, where he led growth initiatives, integration of acquisitions, field force expansion, and portfolio revamps.
User avatar
新しいナラティブ • Nov 12

Driving Revenue Growth And Expanding Market Share Amid Global Challenges

Strategic restructuring and a targeted expansion could enhance market share and revenue growth, particularly in India and Brazil.

CEO報酬分析

Torrent Pharmaceuticals の収益と比較して、Aman Mehta の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2026₹188m₹138m

₹22b

Dec 31 2025n/an/a

₹23b

Sep 30 2025n/an/a

₹21b

Jun 30 2025n/an/a

₹20b

Mar 31 2025₹76m₹76m

₹19b

Dec 31 2024n/an/a

₹19b

Sep 30 2024n/an/a

₹18b

Jun 30 2024n/an/a

₹17b

Mar 31 2024₹66m₹66m

₹17b

Dec 31 2023n/an/a

₹15b

Sep 30 2023n/an/a

₹13b

Jun 30 2023n/an/a

₹13b

Mar 31 2023₹21m₹21m

₹12b

報酬と市場: Amanの 総報酬 ($USD 1.98M ) は、 Indian市場 ($USD 1.10M ) の同規模の企業の平均を上回っています。

報酬と収益: Amanの報酬は過去 1 年間で 20% 以上増加しました。

CEO

Aman Mehta

less than a year
在職期間
₹188,184,000
報酬

Mr. Aman Mehta is MD & Additional Director of J. B. Chemicals & Pharmaceuticals Limited from January 21, 2026. Mr. Mehta serves as Whole-Time Director of Torrent Pharmaceuticals Limited since August 01, 20...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Aman Mehta
MD & Whole-Time Directorless than a year₹188.18m0.000060%
₹ 929.0k
Sudhir Menon
Executive Director of Finance & CFO7.8yrs₹16.30mデータなし
Ashish Hajarnish
Executive Director of Operationsno data₹8.25mデータなし
Geena Malhotra
Chief Technology Officerless than a yearデータなしデータなし
Chintan Trivedi
Company Secretary & Compliance Officer3.8yrsデータなしデータなし
Abdullah Said Al Abri
Chief Customer Service Officer5yrsデータなしデータなし
Sanjay Gupta
President and CEO of Torrent Pharma USAno dataデータなしデータなし
3.8yrs
平均在職期間

経験豊富な経営陣: 500420の経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Aman Mehta
MD & Whole-Time Director3.8yrs₹188.18m0.000060%
₹ 929.0k
Samir Mehta
Chairman37.4yrs₹360.04m0.00024%
₹ 3.7m
Sudhir Mehta
Chairman Emeritus11.9yrsデータなし0.00030%
₹ 4.6m
Nikhil Khattau
Independent Director2.7yrs₹7.60mデータなし
Manish Choksi
Lead Independent Director3.9yrs₹5.30mデータなし
Ameera Shah
Independent Director7.8yrs₹6.10m0.00052%
₹ 8.1m
Nayantara Bali
Independent Director7.3yrs₹7.60mデータなし
Jinal Mehta
Non-Executive Director2.1yrsデータなしデータなし
5.6yrs
平均在職期間
60yo
平均年齢

経験豊富なボード: 500420の 取締役会 は 経験豊富 であると考えられます ( 5.6年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/12 05:17
終値2026/06/12 00:00
収益2026/03/31
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Torrent Pharmaceuticals Limited 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。48

アナリスト機関
Rohit Bhat360 ONE Capital Market Private Limited
Gaurav TinaniAmbit Capital
null nullAntique Stockbroking Ltd.